Mitogen-activated protein kinases (MAPKs), a family of protein serine\threonine kinases regulating cell growth and differentiation, are activated by a dual-specificity kinase through phosphorylation at threonine and tyrosine. We used a recently described selective inhibitor of the p42\p44 mapk -activating enzyme, PD 98059 [2-(2h-amino-3h-methoxyphenyl)-oxanaphthalen-4-one], to investigate the role of the p42\p44 mapk pathway in human platelets. PD 98059 inhibited p42\ p44 mapk activation in thrombin-, collagen-and phorbol esterstimulated platelets, as determined from in-gel renaturation kinase assays, with an IC &! of approx. 5 µM (thrombin stimulation). It also prevented activation of MAPK kinase, which was measured in whole-cell lysates with glutathione S-
INTRODUCTION
Activation of the mitogen-activated protein kinase (MAPK) pathway downstream of receptor tyrosine kinases or G-proteincoupled receptors leads to cell differentiation and cell growth. The kinase cascade, consisting of the three components MAPK kinase kinase, MAPK kinase and MAPK, is conserved throughout eukaryotes [1] . The 42 and 44 kDa isoforms of MAPK [also named extracellular-regulated protein kinases (ERKs) 2 and 1 respectively] are phosphorylated at threonine and tyrosine by MAPK\ERK kinase (MEK). On activation, MAPKs translocate to the nucleus and phosphorylate transcription factors. MAPKs can also phosphorylate cytosolic substrates, including microtubule-associated protein, MAPK-activated protein kinase 1α and 1β [2] [3] [4] and cytosolic phospholipase A # (cPLA # ) [5, 6] . Although much is known about the regulation and role of MAPK in various cell lines, the function of platelet MAPK is not resolved. As platelets are terminally differentiated cells that lack a nucleus, studies on the MAPK pathway focus on its cytosolic substrates. For example, cPLA # becomes phosphorylated in stimulated platelets [7] [8] [9] , and this increases the intrinsic activity of the phospholipase to release arachidonic acid from phospholipids [7] . The ensuing production of thromboxane A # , a potent pro-aggregatory agent, through the activity of cyclo-oxygenase is a major positive-feedback stimulus during platelet aggregation [10] .
From studies in itro and in transfected cells, it was suggested that p42 mapk phosphorylates cPLA # at Ser-505 [5, 6] , which lies within a consensus sequence for MAPK (Pro-Xaa-Ser\Thr-Pro) [11] . After this observation, many groups reported the concomitant activation of MAPK and phosphorylation of cPLA # in stimulated cells [12] [13] [14] [15] [16] [17] . Several recent reports, however, dissociate cPLA # phosphorylation from MAPK activation. Stimu- [18] ; similarly, low concentrations of lipopolysaccharide do not stimulate MAPK but induce phosphorylation of cPLA # [19] . In human platelets, cPLA # is phosphorylated after stimulation with a thrombin receptor agonist peptide that does not induce MAPK phosphorylation [8] . We have previously used the protein kinase C inhibitor Ro 31-8220 to block activation of p42\p44 mapk in platelets stimulated by thrombin or collagen and demonstrated that this affected neither phosphorylation of cPLA # nor release of arachidonic acid [9] .
The present study uses a flavone compound, PD 98059, which has been described as a potent and highly selective inhibitor of MEK [20, 21] , to investigate the role of p42\p44 mapk in platelets. PD 98059 blocks MEK activation, probably through an allosteric mechanism without affecting other kinases such as protein kinase C, protein kinase A, Raf or MAPK itself [21] . We found that inhibition of the MAPK cascade by PD 98059 did not affect platelet responses to the physiological stimuli thrombin and collagen. In particular, cPLA # phosphorylation and activation were not impaired. The results argue against an important physiological role for p42\p44 mapk in primary platelet activation. . Escherichia coli transfected with pGEX2T-ERK2 was a gift of Dr. C. J. Marshall (London, U.K.) from which glutathione S-transferase\p42 mapk fusion protein (GST-MAPK) was expressed and purified as described [22] . [ 
EXPERIMENTAL

Reagents
Preparation of platelets
Blood was drawn by venepuncture from healthy volunteers and washed platelets were prepared as described previously [9] . They were resuspended in Tyrode's buffer (20 mM Hepes, 135 mM NaCl, 3 mM KCl, 0.35 mM Na # HPO % , 12 mM NaHCO $ and 1 mM MgCl #, , pH 7.3) containing the cyclo-oxygenase blocker indomethacin (10 µM) at 4i10) platelets\ml for functional studies, and at 2i10* platelets\ml for immunoprecipitations and kinase assays. Before stimulation, platelets were preincubated with DMSO or PD 98059 for 10 min at 37 mC. For kinase assays and phosphorylation studies, EGTA (1 mM) was present to prevent platelet aggregation. When stimulated by collagen (Nycomed Arzneimittel, Munich, Germany), and for kinase studies, platelets were stirred in a Born lumi-aggregometer at 1200 rev.\min.
MAPK immunoprecipitation and in-gel renaturation kinase assay
p42\p44 mapk were immunoprecipitated with 1 µg of polyclonal anti-p42\p44 mapk antibody (Santa Cruz, Devizes, Wilts., U.K.) and Protein A-Sepharose CL-4B [9] . Immunoprecipitates were resolved on SDS\PAGE [10 % (w\v) gel] with myelin basic protein (MBP ; 0.5 mg\ml) copolymerized in the polyacrylamide. After renaturation, gels were incubated at 37 mC with kinase assay buffer containing 20 µCi\ml of [γ-$#P]ATP, and washed in 5 % (w\v) trichloroacetic acid\1 % Na
. Autoradiographs were exposed for up to 2 days at k70 mC with intensifying screens. The regions corresponding to MAPK were cut from the gels and scintillation-counted for radioactivity.
Total tissue MAPK kinase activity
Platelets were stimulated, lysed on ice in 1 % Triton X-100 (containing 20 mM Tris, pH 8, 40 mM Na % P # O ( , 50 mM NaF, 5 mM MgCl # , 100 µM Na $ VO % , 10 mM EGTA, 2 mM PMSF, 100 nM okadaic acid, 20 µg\ml leupeptin and 20 µg\ml aprotinin), and insoluble material was removed by microcentrifugation at 13 000 g for 15 min at 4 mC. Aliquots (10 µl) were incubated with 30 µl of GST-MAPK buffer (30 mM Tris, pH 7.5, 0.1 mM EGTA, 0.1 % 2-mercaptoethanol, 0.03 % Brij-35, 10 mM MgCl # , 0.2 mM ATP, 100 µg\ml GST-MAPK) at 30 mC for 30 min on a shaking platform. The reaction was terminated by the addition of 40 µl of ice-cold buffer A (50 mM Tris, pH 7.5, 0.1 mM EGTA, 0.4 mM Na $ VO % , 0.1 % 2-mercaptoethanol) containing 20 mM EDTA and 1 mg\ml BSA. To capture GST-MAPK fusion protein, samples were mixed with 20 µl of glutathione-agarose beads [1 : 1 (v\v) in buffer A] at 4 mC for 15 min. Background kinase activity due to non-specific binding of kinases to glutathione-agarose was measured by performing the assay in the absence of GST-MAPK. Beads were washed and incubated with 40 µl of kinase buffer (50 mM Tris, pH 7.5, 0.1 mM EGTA, 12.5 mM MgCl # , 125 µM ATP, 400 µg\ml MBP and 56 µCi\ml [γ-$#P]ATP) at 30 mC for 10 min. The reaction was stopped by spotting 30 µl of supernatant on to P81 phosphocellulose papers and washing these in 75 mM phosphoric acid. Radioactivity of dried filter papers was measured by scintillation counting. Phosphorylation of cPLA 2 cPLA # was immunoprecipitated from [$#P]P i -radiolabelled platelets [9] and resolved on SDS\PAGE (10 % gel). Autoradiographs were taken at k70 mC with intensifying screens. Electrophoretic mobility, to distinguish phosphorylated from non-phosphorylated cPLA # , was analysed from whole-cell lysates on SDS\PAGE (8 % gel) Maxigels.
Immunoblotting
Membranes were incubated with rabbit cPLA # antiserum (1 : 10 000) [7] in Tris-buffered saline\Tween-20 (20 mM Tris, 137 mM NaCl, 0.1 % Tween-20, pH 7.6) containing 1 % (v\v) BSA for 2 h or with polyclonal anti-p44 mapk antibody (2 µg\ml) for 1 h. Blots were washed five times in Tris-buffered saline\ Tween-20 and then incubated with horseradish peroxidaseconjugated donkey anti-rabbit Ig (1 : 20 000). For antiphosphotyrosine immunoblots, monoclonal antibody 4G10 (1 : 1000 ; TCS Biologicals Ltd., Botolph Claydon, Bucks., U.K.) and horseradish peroxidase-conjugated sheep anti-mouse Ig (1 : 10 000) were used. After further washing, blots were developed with the Amersham enhanced chemiluminescence system.
RESULTS
PD 98059 inhibits activation of platelet p42/p44
mapk To determine the inhibiting potential of PD 98059 on p42\p44 mapk activation in platelets, we used an in-gel renaturation kinase assay with MBP as substrate. Preincubation of platelets with PD 98059 at 10 µM decreased thrombin-stimulated activation of p42\p44 mapk by more than 80 %, and completely blocked the response downstream of collagen or PDBu ( Figure  1A ). The IC &! of approx. 5 µM, as determined in thrombinactivated platelets ( Figure 1A) , is similar to the published values of 2 and 10 µM [20, 21] . Using a portion of the MAPK immunoprecipitate, we investigated the effect of PD 98059 on p42\p44 mapk tyrosine phosphorylation, a necessary condition for MAPK activation. PD 98059 prevented tyrosine phosphorylation of p42 mapk in response to thrombin, PDBu ( Figure 1B Indomethacin-pretreated platelets were incubated with DMSO or PD 98059 for 10 min and then stimulated with 1 unit/ml thrombin (), 100 µg/ml collagen or 1 µM PDBu for 2 min. (A) Immunoprecipitates of p42/p44 mapk were resolved on MBP-containing SDS/PAGE (10 % gel) ; gels were renatured and then incubated with 50 µM ATP and 20 µCi/ml of [γ-32 P]ATP in kinase buffer for 1 h at 37 mC. After autoradiographs had been taken from dried gels (left three panels), the MAPK bands were excised and scintillation-counted for radioactivity (right panel). Results are expressed as percentages of thrombin activation (100 % being 4400 c.p.m.). (B) Anti-phosphotyrosine immunoblot of immunoprecipitated p42/p44 mapk (upper panels). The same membranes were immunoblotted for p42/p44 mapk (lower panel).
PD 98059 inhibits MAPK kinase in platelets
Because PD 98059 interfered with tyrosine phosphorylation of MAPK, and because the in-gel kinase assay measured MAPK activity under conditions where PD 98059 was already washed away, the effect of the compound must occur upstream of MAPK rather than at MAPK itself. We therefore measured total MAPK kinase activity from platelet lysates by using a GST-MAPK fusion protein and a kinase assay in itro with MBP as substrate. Incubation of platelets with thrombin for 2 min stimulated MAPK kinase activity by 8.8p1.9-fold over basal activity (after subtraction of background radioactivity ; n l 6). Stimulation in the presence of PD 98059 caused inhibition of MAPK kinase in a concentration-dependent manner (Figure 2) , similar to the effect on MAPK. When PD 98059 was included during incubation of lysates from thrombin-activated platelets with GST-MAPK, it did not reduce MAPK kinase activity (results not shown). These results are in agreement with former reports [20, 21, 23] and show that PD 98059 inhibits activation of MAPK kinase rather than MAPK itself.
PD 98059 does not affect platelet functional responses
We were interested to see whether the inhibition of MEK\MAPK would interfere with primary platelet stimulation. Aggregation and shape change (the initial increase in optical density after stimulation) induced by thrombin (0.05-1 unit\ml) and PDBustimulated aggregation were not changed in the presence of PD 98059 (0.1-100 µM ; example traces are shown in Figure 3A) . Similarly, PD 98059 did not alter collagen-induced increase in light transmission, which is believed to result from a combination of adhesion and aggregation events ( Figure 3A) 
Figure 2 Inhibition of thrombin-induced MAPK kinase activation by PD 98059
Indomethacin-treated platelets were incubated with DMSO or PD 98059 for 10 min and then with 1 unit/ml thrombin for 2 min. Aliquots of platelet lysates were incubated with 100 µg/ml GST-MAPK. Activation of GST-MAPK was determined in a kinase reaction as described in the Experimental section. The radioactivity of controls where the platelet lysate was replaced by H 2 O was subtracted. Typical values for basal (unstimulated platelets, set as 0 %) and thrombinstimulated platelets (set as 100 %) were 500 and 2500 c.p.m. respectively. Results are given as meanspS.E.M. (n l 3-6).
PD 98059 did not inhibit the increase in intracellular Ca# + concentration stimulated by thrombin or collagen, as measured in fura 2-labelled platelets (results not shown). Because PD 98059 is a kinase inhibitor, we checked whether it would inhibit protein kinase C, an important kinase mediating platelet responses [10, 24] . The compound had no significant effect on thrombin-or collagen-stimulated $#P phosphorylation of pleckstrin, the protein kinase C substrate [25] . Some kinase inhibitors can, paradoxically, induce activation of kinases or protein phosphorylation through inhibition of negative regulatory mechanisms [26] . The presence of PD 98059 did not change the pattern or intensities of total tissue $#P phosphorylation or of tyrosine phosphorylation, which was determined by immunoblots using the monoclonal anti-phosphotyrosine antibody 4G10 (results not shown). This indicates that the compound does not unspecifically affect kinase activity, which is in agreement with the lack of inhibition of PD 98059 on protein serine\threonine kinase activities in itro [23] .
Effect of PD 98059 on cPLA 2 phosphorylation
In transfected Chinese hamster ovary cells, MAPK phosphorylates, and thereby regulates, cPLA # [5, 6] . Autoradiographs of immunoprecipitated cPLA # from [$#P]P i -labelled platelets show that thrombin-and collagen-induced phosphorylation was not altered significantly in the presence of PD 98059 (Figure 4) . To investigate the time course of cPLA # phosphorylation more closely, we performed electrophoretic mobility shift assays [27] whereby the phosphorylated form of cPLA # , which moves more slowly on SDS\PAGE, is detected as a second band in immunoblots. Thrombin-induced cPLA # phosphorylation was detectable after 2 min of stimulation (approximately half of the protein converted to the phosphorylated form) and cPLA # was completely transformed to the more slowly migrating band after 10 min of stimulation ; PD 98059 did not change this pattern (results not shown). Similar Indomethacin-treated [ 32 P]P i -labelled platelets were incubated with 1 % DMSO or 20 µM PD 98059 for 10 min and then stimulated with 1 unit/ml thrombin (T) for 2 min or with 100 µg/ml collagen (C) for 5 min. cPLA 2 was immunoprecipitated, resolved on SDS/PAGE (10 % gel) and autoradiographed. Similar amounts of cPLA 2 were immunoprecipitated in all samples (results not shown).
results were obtained from collagen-treated platelets where the phosphorylated form of cPLA # can be detected at 5 and 10 min (results not shown). cPLA # phosphorylation was therefore not altered significantly under conditions when p42\p44 mapk activation was inhibited.
Stimulation of platelets by Ca 2 + ionophore and phorbol ester
Phorbol ester-induced activation of protein kinase C has a synergistic effect on Ca# + ionophore-activated release of 5-HT and arachidonic acid [24, 28] . We were interested to test the role of p42\p44 mapk in these responses. Preincubation of platelets with PD 98059 did not interfere with the synergistic release of [$H]5-HT stimulated by A23187 in the presence of PDBu ( Figure  5A ) but blocked the effect of PDBu on A23187-induced [$H]arachidonic acid release ( Figure 5B ; stimulation time 2 min). PDBu-induced phosphorylation of cPLA # can be detected after 5 min of stimulation ( Figure 5C ). In agreement with the inhibition of [$H]arachidonic acid release by PD 98059, PDBu-induced cPLA # phosphorylation was fully blocked in the presence of the compound after 5 min of stimulation ( Figure 5C ). However, partial phosphorylation of cPLA # was detected after 10 min of stimulation in the presence of PD 98059, which might be due to activation of a kinase that is not blocked by PD 98059. 
DISCUSSION
The MEK inhibitor PD 98059 has recently been used to confirm the role of p42\p44 mapk in cell differentiation and growth [20, 21] and in insulin and insulin-like growth factor signalling [29, 30] . Alessi et al. [23] propose in a detailed study on the effects of PD 98059 in itro and in i o that PD 98059 acts by binding to the inactivated form of MAPK kinase and thereby prevents its phosphorylation through the activity of c-Raf. Thus the degree of inhibition of MAPK and downstream kinases by PD 98059 in i o depends on the strength of Raf stimulation brought about by the agonist used. The increased potency of PD 98059 on MAPK inhibition in platelets compared with Swiss 3T3 cells [23] might be due to a smaller activation of the MAPK pathway in indomethacin-treated platelets by the stimuli employed. The subtypes of MAPK kinases that are present in platelets are not known. PD 98059 seems to be more selective in blocking activation of the MAPK kinase 1 isoform (IC &! 2-7 µM) than MAPK kinase 2 (IC &! 50 µM) [23] , and because activation of GST-MAPK by MAPK kinase in whole-cell lysates was completely inhibited in the presence of 20 µM PD 98059, MAPK kinase 1 might be the predominant isoform present in platelets. By immunoblotting with a polyclonal antibody (Santa Cruz), we detected p74 Raf-" in platelet lysates (results not shown), which might act as an MAPK kinase kinase [3] . Whether Raf is activated in human platelets has still to be determined.
In the present study we verified the inhibitory action of PD 98059 towards MAPK kinase, towards p42\p44 mapk tyrosine phosphorylation and activation, and its specificity. Platelet responses, such as increase in Ca# + concentration, phosphorylation of pleckstrin, and release of 5-HT and arachidonic acid, were not altered significantly by the inhibitor. The results obtained with PD 98059 on cPLA # phosphorylation are in agreement with our recent report [9] , where we show that inhibition of the p42\p44 mapk cascade does not interfere with thrombin-and collagen-stimulated cPLA # activation or phosphorylation. Interestingly, PDBu-induced potentiation of A23187-stimulated arachidonic acid release and PDBu-induced cPLA # phosphorylation were blocked by PD 98059. This suggests that p42\p44 mapk are able to phosphorylate cPLA # in platelets and thereby enhance phospholipase activity, but only after activation by phorbol esters. Thus the physiological activation of phospholipase C, which leads to an increase in intracellular Ca# + concentration and activation of protein kinase C, stimulates a different pathway mediating cPLA # phosphorylation compared with combination of Ca# + ionophore and phorbol ester. One possible explanation of this paradoxical observation lies in the complexity of signalling networks. Stimulation at the receptor level is expected not only to have effects on activatory pathways, but also to start inhibitory mechanisms, for example an increase in phosphatase activity, that are responsible for the termination of stimulation and the return of cell activity to basal. It might be that stimulation at the level of protein kinase C by PDBu fails to activate such negative regulatory mechanisms, or that an unphysiologically robust activation of protein kinase C gives rise to effects that are not observed otherwise. Alternatively, PDBu might activate protein kinase C subtypes in different time courses or compartments of the cell, or with different intensities compared with thrombin and collagen. Additionally, the use of PD 98059 has demonstrated that potentiation of 5-HT release by PDBu in Ca# + ionophore-treated platelets is not related to activation of p42\p44 mapk .
Previous studies in platelets [8, 9] and the present report suggest that a proline-directed kinase other than p42\p44 mapk phosphorylates cPLA # . Candidate kinases would be members of the stress-activated protein kinase family [31, 32] , which are not inhibited by PD 98059 [23, 30] . Recently Kramer et al. [33] measured the activity of a proline-directed kinase in fractions obtained from platelet lysates by partial purification, which contained the p38 isoform of stress-activated protein kinase. To investigate further the regulation of cPLA # in platelets it will be interesting to see whether immunoprecipitates of this stressactivated protein kinase are stimulated in platelets by thrombin and collagen, and whether specific inhibition of this kinase would affect cPLA # phosphorylation and activation.
